AP
PCRX icon

AHL Partners’s Pacira BioSciences PCRX Stock Holding History

AHL Partners’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$241K Buy
+5,284
New +$209K ﹤0.01% 1199
2016
Q1 		– Sell
-11,567
Closed -$889K – 808
2015
Q4 		$889K Buy
+11,567
New +$655K 0.07% 373
2015
Q3 		– Sell
-17,962
Closed -$1.27M – 784
2015
Q2 		$1.27M Buy
17,962
+7,694
+75% +$606K 0.05% 506
2015
Q1 		$913K Buy
+10,268
New +$1.04M 0.04% 577

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

AHL Partners's PCRX Position: Q4 2017 in Review

AHL Partners opened a new position in Pacira BioSciences (PCRX) in Q4 2017: 5,284 shares worth $241K. The stake represents ﹤0.01% of the portfolio and ranks #1199 among its holdings. This is a return to the name: AHL Partners previously reported a position in PCRX as recently as Q4 2015.

AHL Partners first reported a position in PCRX in Q1 2015 and has held it in 4 quarters since. The position peaked at $1.27M in Q2 2015. 185 funds tracked by Wall St. Rank hold PCRX as of Q4 2017.

  • AHL Partners held 5,284 shares of Pacira BioSciences worth $241K as of Q4 2017.
  • Pacira BioSciences was a new AHL Partners position in Q4 2017.
  • Pacira BioSciences made up ﹤0.01% of AHL Partners's portfolio in Q4 2017, its #1199 holding.
  • AHL Partners first reported a position in Pacira BioSciences in Q1 2015 and has held it in 4 quarters since.
  • AHL Partners's Pacira BioSciences position peaked at $1.27M in Q2 2015.
  • 185 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2017.

Based on AHL Partners's 13F filing for Q4 2017, filed 14 Feb 2018.